Evidence map›Paper›PMID 37735619›Full record

ArticleNature structural & molecular biology2023

Time-resolved cryo-EM (TR-EM) analysis of substrate polyubiquitination by the RING E3 anaphase-promoting complex/cyclosome (APC/C).

Tatyana Bodrug, Kaeli A Welsh, Derek L Bolhuis, Ethan Paulаkonis, Raquel C Martinez-Chacin, Bei Liu, Nicholas Pinkin, Thomas Bonacci, Liying Cui, Pengning Xu and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Journal of medicinal chemistry · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. [High expression of UBE2S promotes progression of hepatocellular carcinoma by increasing cancer cell stemness].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Tatyana BodrugDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Kaeli A WelshDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Derek L BolhuisDepartment of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0002-9062-9739
Ethan PaulаkonisDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Raquel C Martinez-ChacinDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Bei LiuDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Nicholas PinkinDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Thomas BonacciDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Liying CuiDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Pengning XuDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Olivia RoscowDepartment of Molecular and Cellular Biology, College of Biological Science, University of Guelph, Guelph, Ontario, Canada.
Sascha Josef AmannResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.
Irina GrishkovskayaResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria.ORCID 0000-0003-0164-9373
Michael J EmanueleDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-4104-7449
Joseph S HarrisonDepartment of Chemistry, University of the Pacific, Stockton, CA, USA.ORCID 0000-0002-2118-6524
Joshua P SteimelSchool of Engineering, California Polytechnic State University Humboldt, Arcata, CA, USA.
Klaus M HahnDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0002-1970-7562
Wei ZhangDepartment of Molecular and Cellular Biology, College of Biological Science, University of Guelph, Guelph, Ontario, Canada.
Ellen D ZhongDepartment of Computer Science, Princeton University, Princeton, NJ, USA.ORCID 0000-0001-6345-1907
David HaselbachResearch Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria. david.haselbach@imp.ac.at.ORCID 0000-0002-5276-5633
Nicholas G BrownDepartment of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. nbrown1@med.unc.edu.ORCID 0000-0002-6141-0164
University of North Carolina at Chapel Hill · USResearch Institute of Molecular Pathology · ATUniversity of Guelph · CACalifornia Polytechnic State University · USPrinceton University · USUniversity of the Pacific · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Dissecting signaling in vivo via precise control and visualization of protein activityR35GM122596 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Klaus M. Hahn · 2017 to 2026
$7.4M
UTSW-UNC Center for Cell Signaling AnalysisRM1GM145399 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Kevin Michael Dean, Klaus M. Hahn · 2022 to 2026
$6.2M
MOLECULAR AND CELLULAR BIOPHYSICS TRAINING PROGRAMT32GM008570 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KUHLMAN, BRIAN A, SLEP, KEVIN C · 1995 to 2022
$5.1M
Spindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1M
Predoctoral Training in the Pharmacological SciencesT32GM135095 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph Mauro Calabrese, Michael James Emanuele · 2020 to 2026
$3.6M
SCF Ubiquitin Ligases in Cell Cycle Control and Chromosome StabilityR01GM120309 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2016 to 2023
$2.3M
Deubiquitinases in Cell Cycle ControlR01GM134231 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2020 to 2023
$1.6M
NCI NIH HHS P30 CA016086NIGMS NIH HHS R01 GM120309NIGMS NIH HHS R01 GM134231NIGMS NIH HHS R35 GM122596NIGMS NIH HHS R35 GM128855NIGMS NIH HHS RM1 GM145399NIGMS NIH HHS T32 GM008570NIGMS NIH HHS T32 GM135095
6 · The paper itself

Abstract

Substrate polyubiquitination drives a myriad of cellular processes, including the cell cycle, apoptosis and immune responses. Polyubiquitination is highly dynamic, and obtaining mechanistic insight has thus far required artificially trapped structures to stabilize specific steps along the enzymatic process. So far, how any ubiquitin ligase builds a proteasomal degradation signal, which is canonically regarded as four or more ubiquitins, remains unclear. Here we present time-resolved cryogenic electron microscopy studies of the 1.2 MDa E3 ubiquitin ligase, known as the anaphase-promoting complex/cyclosome (APC/C), and its E2 co-enzymes (UBE2C/UBCH10 and UBE2S) during substrate polyubiquitination. Using cryoDRGN (Deep Reconstructing Generative Networks), a neural network-based approach, we reconstruct the conformational changes undergone by the human APC/C during polyubiquitination, directly visualize an active E3-E2 pair modifying its substrate, and identify unexpected interactions between multiple ubiquitins with parts of the APC/C machinery, including its coactivator CDH1. Together, we demonstrate how modification of substrates with nascent ubiquitin chains helps to potentiate processive substrate polyubiquitination, allowing us to model how a ubiquitin ligase builds a proteasomal degradation signal.

Indexed as

AnaphaseUbiquitinAnaphase-Promoting Complex-CyclosomeCell Cycle ProteinsCryoelectron MicroscopyHumansUbiquitinationAnaphase-Promoting Complex-CyclosomeCell Cycle ProteinsUbiquitin

Identifiers

PMID37735619
PMCPMC10643132
OpenAlexW4386923466

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.